Research guide

Bimagrumab

BYM338

An investigational antibody studied for muscle and body-composition conditions.

Compare
Product statusInvestigational
Development snapshotPhase 2 evidence base

How it works, simply

It blocks activin type II receptors, which participate in signals that limit muscle growth.

What the evidence tells us

More lean mass does not necessarily mean better strength or function. This is an antibody, not a small peptide vial.

No study-by-study evidence summary has been verified for this profile yet. The explanation above describes its purpose and limits, not a proven benefit for every use.

Watch with PEP 7

A short introduction; the sources and limitations remain important.

Open video guide

Video guides are coming soon.

Risks and open questions

This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.

Research and education only. PepGuide does not recommend medicines, doses or protocols.

Technical details and study context

Mechanism: Blocks activin type II receptor signaling, including pathways that restrain muscle growth.

Sponsor or developer: Clinical-stage developer

Studied or labeled topics: Body-composition research, Muscle-wasting research, Obesity research

Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.

Sources and review dates

Product labels and further research

These directories help locate records. They are not individual studies supporting every statement.

Readability updated October 10, 2026. Evidence review: Primary-source review pending. A wording update is not a new clinical review.